Drugs in Pregnancy and Lactation: Tenth Edition

ALEFACEPT

Immunologic Agent (Immunosuppressant)

PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk

BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity

PREGNANCY SUMMARY

No reports describing the use of alefacept in human pregnancy have been located. The animal data suggest that the human embryo and fetal risk are low, but the absence of human pregnancy experience prevents a full assessment of the risk. Psoriasis is common in women of childbearing potential (1). Combined with the very long elimination half-life, this suggests that exposure of inadvertent pregnancies is highly probable. Although the effects on pregnancy are unknown, there is a potential that alefacept could adversely affect the development of the fetal immune system and the immune function of the infant. Health care professionals are encouraged to enroll women who became pregnant while being treated with alefacept in the Biogen Pregnancy Registry by calling 1-866-263-8483 (1).

FETAL RISK SUMMARY

Alefacept is an immunosuppressive dimeric fusion protein consisting of a portion of the human leukocyte function antigen-3 linked to the Fc portion of immunoglobulin G (IgG1) produced by recombinant DNA technology. Alefacept is indicated for the treatment of moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy. The drug is administered either IM or IV. After an IV dose, the mean elimination half-life was about 270 hours (about 11 days) (1).

Reproduction studies with alefacept have been conducted in cynomolgus monkeys. At doses about 62 times the human dose based on body weight (HD), no evidence of impaired fertility or fetal harm was observed. Weekly IV bolus doses administered during organogenesis were not abortifacient or teratogenic. Alefacept crossed the placenta in monkeys producing fetal concentrations that were 23% of the maternal concentrations. No evidence of fetal toxicity or adverse effects on immune system development was observed in the exposed fetuses (1).

In long-term studies in cynomolgus monkeys with weekly IV doses that were 12 or 248 times the HD, one animal in the high-dose group developed a β-cell lymphoma. Other animals in both groups developed β-cell hyperplasia of the spleen and lymph nodes. All animals were positive for an endemic primate gammaherpesvirus. It is known that the immune suppression of animals infected with this virus may lead to β-cell lymphomas (1). Hyperplasia of β-cell-dependent regions in baboon spleens was observed in another low-dose study. Carcinogenicity and fertility studies were not conducted with alefacept, but mutagenicity assays, both in vitro and in vivo, were negative (1).

It is not known if alefacept crosses the human placenta. The monkey and human placentas are classified as hemomonochorial and, since the drug crosses the monkey placenta, it probably crosses the human placenta as well. The human fetal exposure to the drug should be similar to that observed in monkeys.

BREASTFEEDING SUMMARY

No reports describing the use of alefacept during human lactation have been located. As an immune globulin, the drug is probably excreted into breast milk. Moreover, because of the very long elimination half-life (about 11 days), holding breastfeeding after a dose to allow clearance from the mother’s system is not practical. The effect of this exposure on a nursing infant is unknown, but the dimeric fusion protein would most likely undergo some degree of digestion in the infant’s gut. However, suppression of a nursing infant’s immune function is a potential complication. Until data are available, avoiding nursing during the use of alefacept is the safest course.

Reference

1.Product information. Amevive. Biogen Idec, 2005.



If you find an error or have any questions, please email us at admin@doctorlib.org. Thank you!